Thermo Fisher Scientific Acquires Affinity BioReagents
News Jul 18, 2008
Thermo Fisher Scientific Inc. has announced that it has acquired Affinity BioReagents, a provider of antibodies, peptides, proteins and other reagents for life science research, based in Golden, Colorado.
“Affinity BioReagents is an ideal complement to our existing capabilities in protein research,” said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific.
“This acquisition enhances our extensive antibody portfolio, which will drive growth as we combine these reagents with our current proteomics offerings to create end-to-end solutions for widely used protein-research applications.” Such applications include Western blotting, ELISA, immunohistochemistry, flow cytometry and mass spectroscopy.
Affinity BioReagents has an offering of more than 35,000 reagents – primarily monoclonal and polyclonal antibodies – which are used in numerous fields of medical and academic research, as well as drug discovery.
The company also provides recombinant proteins and custom antibody-production services. Affinity BioReagents had annual revenues of approximately $6 million in 2007, and will be integrated into Thermo Fisher’s Analytical Technologies Segment.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE